Last updated: June 1, 2026
LOVENOX (Preservative Free) Suppliers: What companies make and supply enoxaparin products for the US market
LOVENOX (enoxaparin sodium) preservative-free product sourcing is anchored on vertically integrated manufacturing of the active ingredient (enoxaparin sodium) and finished sterile bulk/filled dosage forms. The key “supplier” in the market is Sanofi’s manufacturing network for enoxaparin and finished product, with additional supply dependencies tied to contract sterilization/fill-finish capacity used for specific presentations and geographies.
The preservative-free version is a different presentation than standard multidose vials, and supply can shift by presentation, geography, and FDA lot release. The operating reality for procurement, licensing, and substitution risk is that supply continuity is driven by the small number of qualified sterile fill-finish nodes plus Sanofi’s upstream heparin-source and depolymerization capacity.
Who supplies LOVENOX (preservative free) enoxaparin sodium in the US?
Primary supplier (brand owner and commercial source): Sanofi.
LOVENOX is manufactured and marketed by Sanofi entities, and the “supplier” for US commercial inventory is Sanofi’s distribution chain (manufacturing sites plus FDA-lot release).
Upstream and finished-product sourcing logic
- Upstream: enoxaparin sodium is produced through controlled depolymerization from porcine heparin, with multiple quality and safety steps (anticoagulant activity and molecular weight distribution controls).
- Downstream: sterile solution fill and packaging for the specific dosage form (including preservative-free presentations) is typically handled at specialized sterile fill-finish lines, which can be bottleneck capacity.
Procurement implication
For preservative-free presentations, substitutions typically mean switching finished dosage forms or presentations, not switching the active ingredient supplier. The active is still enoxaparin sodium, and the qualified finished product inventory is tied to Sanofi’s approved manufacturing network and approved label presentation.
What companies make the active ingredient enoxaparin sodium for LOVENOX?
Sanofi is the critical active-ingredient source for LOVENOX commercialization.
In practice, the active ingredient supply for LOVENOX is not a broad, multi-vendor commodity. It is tied to Sanofi’s validated enoxaparin production and lot release under the company’s regulatory filings for the finished product.
Active ingredient supply constraints that matter
- Source material variability for porcine heparin feedstock
- Depolymerization control and batch-to-batch consistency for molecular weight distribution
- Analytical release and stability profiles that must match the finished preservative-free presentation requirements
Why this affects supplier decisions
Procurement and licensing teams usually treat enoxaparin sodium as a “single qualified system,” where the supplier is effectively the same company that holds the finished-product regulatory approvals and manufacturing validation for the presentation.
Which contract manufacturers supply sterile fill-finish for LOVENOX preservative-free?
This presentation-specific fill-finish capacity is controlled through Sanofi’s approved manufacturing sites and, in some instances, contract sterile operations used for specific plants or regions.
The “supplier list” for preservative-free finished dosage forms is therefore not a simple enumerated roster across the entire industry.
What to expect operationally
- Sterile solution filling and packaging are concentrated in a limited number of GMP facilities with validated aseptic processes.
- Lot release and stability testing requirements link finished product packaging format to the specific approved fill-finish node.
Business impact
If a facility is down or a sterilization/fill-finish line is under change control, the brand’s preservative-free supply can tighten even if upstream enoxaparin capacity exists.
How do Sanofi manufacturing sites affect LOVENOX preservative-free supply?
Sanofi’s site network is the governing factor for continuity.
Supply risk is best modeled at the manufacturing step level:
- Active ingredient manufacturing batch availability
- Sterile bulk preparation
- Aseptic fill-finish and packaging line readiness
- FDA release timelines and distribution scheduling
Key operational point
Preservative-free presentation is more sensitive to aseptic technique control and container-closure integrity requirements, so fill-finish disruptions can show up earlier in preservative-free channels than in less stringent multidose presentations.
What supply dependencies exist for LOVENOX preservative-free drug product?
Dependency stack
- Heparin source and depolymerization capacity for enoxaparin sodium
- Sterile bulk and filtration steps tied to validated aseptic processing
- Aseptic fill-finish line capacity for preservative-free container systems
- Packaging component supply (needles, syringes, plungers, labels, cartons) that must match Sanofi’s approved configuration
Where procurement risk concentrates
- Aseptic fill-finish capacity is the highest leverage constraint for preservative-free.
- Packaging component substitutions can be restricted by approved comparability and lot release requirements.
Does the preservative-free LOVENOX presentation change the supplier landscape?
It narrows it.
Compared with standard multidose formats, preservative-free presentations usually rely on stricter aseptic/closure integrity controls and container-closure systems. That tends to reduce the universe of qualified fill-finish providers that can be used without major regulatory work.
Practical supplier effect
- Even if multiple plants can produce enoxaparin sodium, fewer plants may be approved for the specific preservative-free syringe/format.
- Supply contracts and qualified vendor lists tend to be presentation-specific.
What generic or biosimilar suppliers need to replicate enoxaparin sodium for the preservative-free format?
The barrier is not only the API supplier.
Competitors must replicate:
- enoxaparin sodium quality attributes (including molecular weight distribution and anticoagulant potency)
- finished product sterility assurance system
- preservative-free container closure and aseptic process controls
Implication for entry risk
Even when generic manufacturers can source enoxaparin sodium, replicating the finished preservative-free sterile product to FDA requirements and matching label-specific presentation is the gating factor.
Orange Book and FDA regulatory filings: Who is listed as the applicant/manufacturer for preservative-free LOVENOX?
The defining regulatory “supplier” for the US market is the FDA NDA holder and the listed drug product manufacturer(s) for each strength and dosage form. Those listings map to:
- NDA applicant and marketing authorization holder
- Manufacturer/packer codes on FDA labels and drug listings
- Approved manufacturing sites tied to the preservative-free presentation
Business action
For licensing, substitution, or supply chain due diligence, supplier identification must be anchored to the specific NDC(s) and the FDA label/manufacturer information tied to the preservative-free presentation.
Supply chain diligence checklist for LOVENOX preservative-free procurement
To evaluate suppliers and continuity in a high-stakes procurement setting, focus on:
- NDC-specific manufacturer and packer information from the prescribing label
- Batch release lead times for preservative-free presentation NDCs
- Qualification status of fill-finish nodes and recent manufacturing change controls
- Packaging component sourcing stability for syringe and closure components
- Regulatory link between API lots and finished product lot release within Sanofi’s system
Key Takeaways
- Sanofi is the primary supplier and the controlling commercial source for LOVENOX preservative-free inventory in the US.
- “Suppliers” for the finished preservative-free presentation are largely determined by Sanofi’s approved sterile fill-finish and packaging network rather than a broad market of interchangeable contract manufacturers.
- Supply continuity risk concentrates at sterile fill-finish and presentation-specific container-closure systems even when upstream enoxaparin capacity exists.
- For due diligence, supplier identification should be NDC-specific and tied to FDA label/manufacturer listings for the preservative-free presentation.
FAQs
1) Which NDCs correspond to LOVENOX preservative-free syringes and who is the listed manufacturer?
Manufacturer identity is NDC-specific; use the NDC-level label/manufacturer listing tied to the preservative-free presentation.
2) Can contract manufacturers produce enoxaparin sodium for LOVENOX preservative-free finished product?
Contracting is generally limited by the need for FDA-approved manufacturing and sterile fill-finish validation tied to the preservative-free format.
3) Do preservative-free LOVENOX shortages relate to API capacity or fill-finish capacity?
In practice, preservative-free shortages are more sensitive to sterile fill-finish capacity and container closure qualification than to upstream API capacity alone.
4) What supply risks affect the sterile preservative-free container closure system?
Closure integrity, packaging component availability, and aseptic fill-finish line readiness are the primary constraints.
5) How can a generic manufacturer mitigate supply chain barriers for a preservative-free enoxaparin product?
By securing validated enoxaparin sourcing and building/qualifying preservative-free sterile fill-finish processes tied to FDA comparability requirements for the finished presentation.
References (APA)
- FDA. (n.d.). Drug databases: Orange Book and drug labeling/NDAs. U.S. Food and Drug Administration.
- Sanofi. (n.d.). Product labeling and manufacturing information for Lovenox (enoxaparin sodium). Sanofi.
